Сравнение
Enfuvirtid vs. LL-37
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
159519-65-0
597562-32-8
Молекулярная масса
4491.88 g/mol
4493.33 g/mol
Период полувыведения
нет данных
нет данных
Последовательность
нет данных
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESМеханизм действия
Enfuvirtid
Enfuvirtide binds the first heptad-repeat region (HR1) of the gp41 subunit of the HIV envelope protein. This prevents the conformational change required for fusion of the viral and cell membranes — the virus cannot enter the cell.
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Доказательная база
Наивысшая доказательность
РКИ на людях
Исследование на людях
Исследования
1
4
из них на людях
1
1
Зафиксированные эффекты
2
4
Открытые противоречия
0
1
Задокументированные нежелательные явления
1
0
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Enfuvirtid and LL-37?
- Enfuvirtid is classified as "Исследования (прочее)", while LL-37 is classified as "Исследования (прочее)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Enfuvirtid or LL-37?
- The highest available evidence level is "РКИ на людях" for Enfuvirtid and "Исследование на людях" for LL-37. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Enfuvirtid and LL-37 in Germany and the United States?
- Германия: Enfuvirtid — Рецептурный, LL-37 — Только для исследований. США: Enfuvirtid — Рецептурный, LL-37 — Только для исследований. These are factual summaries with source and review date on the individual pages.